Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Speciality MedicinesBOM:544738 -6.76%21 9-Day RSI is 18.85 as of Aug. 09, 2026. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 1,046 Drug Manufacturers companies, Speciality Medicines ranks better than 97.61% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Speciality Medicines 9-Day RSI Related Terms
BOM:544738 vs ZTS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Speciality Medicines's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Speciality Medicines 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Speciality Medicines's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Speciality Medicines's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Speciality Medicines (BOM:544738) has a 9-Day RSI of 18.85 as of Aug. 09, 2026. According to the industry distribution chart, Speciality Medicines ranks #25 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 2.4%.
Is Speciality Medicines' 9-Day RSI too high?
Speciality Medicines' current 9-Day RSI is 18.85. The Drug Manufacturers industry median 9-Day RSI is 55.37. Speciality Medicines' value of 18.85 is 66% below this industry median. Based on the distribution chart, Speciality Medicines ranks #25 out of 1046 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' 9-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Speciality Medicines ranks #25 out of 1046 companies for 9-Day RSI. This places Speciality Medicines in the top 2% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 55.37. Speciality Medicines' value of 18.85 is 66% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 55.37, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Speciality Medicines's current 9-Day RSI of 18.85 is 66% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 55.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Speciality Medicines's current 9-Day RSI is 18.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current 9-Day RSI of 18.85. The current 9-Day RSI is 18.85 and 66% below the Drug Manufacturers industry median of 55.37. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current 9-Day RSI is 18.85 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score
Get the complete analysis for BOM:544738
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544738 has been successfully added to your 
